Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Ameriprise Financial Inc.

Ameriprise Financial Inc. lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 224,988 shares of the biotechnology company’s stock after buying an additional 5,732 shares during the period. Ameriprise Financial Inc. owned approximately 0.18% of Arrowhead Pharmaceuticals worth $4,230,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ARWR. First Citizens Bank & Trust Co. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $205,000. KBC Group NV increased its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after buying an additional 1,644 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 11.6% during the 4th quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company’s stock worth $525,000 after buying an additional 2,907 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $38,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,385 shares of the biotechnology company’s stock worth $496,000 after buying an additional 2,475 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ARWR shares. Royal Bank of Canada restated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a report on Tuesday, May 13th. B. Riley reiterated a “buy” rating and issued a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $42.13.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the transaction, the chief executive officer now owns 3,773,802 shares of the company’s stock, valued at approximately $64,230,110.04. This trade represents a 3.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 275,880 shares of company stock valued at $4,034,037. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $15.13 on Monday. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm has a 50-day moving average of $13.32 and a two-hundred day moving average of $17.61. The stock has a market cap of $2.09 billion, a P/E ratio of -2.93 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts’ expectations of $116.27 million. During the same period in the previous year, the company earned ($1.02) earnings per share. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.